The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions
Abstract
Summary: Three platelet glycoprotein (GP) IIb/IIIa receptor antagonists have been approved as adjunctive therapy to decrease the ischemic complications of percutaneous coronary interventions (PCI) and/or unstable angina. They include the chimeric murine/human monoclonal antibody 7E3 Fab fragment (abciximab), a cyclic heptapeptide based on the KGD amino acid sequence (eptifibatide), and a nonpeptide mimetic of the RGD sequence (tirofiban). The agents are very effective in providing both short-term and long-term benefit after PCI, and one agent has also demonstrated a progressive long-term mortality benefit. The long-term mortality benefit is highly cost-effective when compared to other medical interventions. The benefits in treating unstable angina without PCI are less dramatic and robust, with some agents providing no benefit. Severe thrombocytopenia is an infrequent, but potentially serious, complication of therapy with all of the agents. The risk of major bleeding is increased only minimally or not at all by the drugs. Currently, a number of new indications for GPIIb/IIIa antagonists are under study, including acute myocardial infarction (± thrombolytic therapy, ± PCI) and stroke. In addition to their impact on improving outcome, the results of clinical trials with these agents provide crucial insights into the contribution of GPIIb/IIIa-mediated platelet function in the pathophysiology of thrombotic vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Cited by
Takagi, J., Petre, B. M., Walz, T., & Springer, T. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00935-2 · Cited by 1,168
Berrier, A. L., & Yamada, K. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21237 · Cited by 957
Integrins: dynamic scaffolds for adhesion and signaling in platelets
Shattil, S. J., & Newman, P. J. (2004) · Blood · doi:10.1182/blood-2004-04-1257 · Cited by 601
Platelet Activation and Blood Coagulation
Bevers, E., Lindhout, T., & Heemskerk, J. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613209 · Cited by 584
Gogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J. V., & Samama, C. M. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32833f6f6f · Cited by 529
Metadata
- Authors
- Coller, B.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 86
- Issue
- 07
- Pages
- 427-443
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1834731714
- Cited by
- 185
- References
- 1
- FWCI
- 13.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions. https://app.cochat.ai/papers/10.1055/s-0037-1616241
- The paper
- Coller, B. (2001). Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1616241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.